Oncology

Advances in early detection, prevention, and treatment are reshaping the outlook for pancreatic cancer, one of the deadliest malignancies worldwide.

Patients with unresectable pancreatic cancer who receive second-line treatment with nanoliposomal irinotecan in combination with fluorouracil and folinic acid may remain eligible for subsequent third-line chemotherapy.

Clinical cancer research across the Asia-Pacific region faces substantial barriers, with competing demands, lack of funding, and limited infrastructure emerging as the most significant obstacles, according to a large cross-sectional survey of healthcare professionals.

Machine learning can help predict urgent care visits in patients with non–small cell lung cancer receiving systemic therapy.

Long-term head and neck cancer survivors frequently report poor oral health-related quality of life, with persistent late toxicities remaining common more than 8 years after diagnosis.

AI is rapidly transforming oncology, but many clinicians lack practical tools to evaluate its real-world reliability.

Acute diarrhea during chemoradiotherapy for anal cancer is significantly more likely among patients treated with 5-fluorouracil (5-FU) or capecitabine compared with those receiving cisplatin or radiotherapy alone, according to new findings.

Overall survival in the Asia cohort of the Phase III MARIPOSA study has been reported to favor amivantamab combined with lazertinib compared with osimertinib monotherapy in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).